Cerity Partners
SNDX icon

Cerity Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Cerity Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Sell
17,623
-21,460
-55% -$446K ﹤0.01% 2614
2026
Q1 		$913K Buy
39,083
+10,227
+35% +$222K ﹤0.01% 1912
2025
Q4 		$606K Buy
28,856
+2,082
+8% +$36.3K ﹤0.01% 1986
2025
Q3 		$412K Buy
+26,774
New +$350K ﹤0.01% 2096
2025
Q2 		– Sell
-24,048
Closed -$295K – 2752
2025
Q1 		$295K Buy
+24,048
New +$339K ﹤0.01% 2024

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cerity Partners's SNDX Position: Q2 2026 in Review

Cerity Partners reduced its Syndax Pharmaceuticals (SNDX) stake by 55% in Q2 2026, selling an estimated $446K and leaving 17,623 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Cerity Partners first reported a position in SNDX in Q1 2025 and has held it in 5 quarters since. The position peaked at $913K in Q1 2026. 218 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Cerity Partners held 17,623 shares of Syndax Pharmaceuticals worth $385K as of Q2 2026.
  • Cerity Partners sold 21,460 Syndax Pharmaceuticals shares in Q2 2026, an estimated $446K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2614 holding.
  • Cerity Partners first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Cerity Partners's Syndax Pharmaceuticals position peaked at $913K in Q1 2026.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.